Share on StockTwits

Tekmira Pharmaceuticals (NASDAQ:TKMR) is set to announce its Q214 earnings results on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.26) per share and revenue of $3.72 million for the quarter.

Shares of Tekmira Pharmaceuticals (NASDAQ:TKMR) opened at 23.80 on Tuesday. Tekmira Pharmaceuticals has a one year low of $5.08 and a one year high of $31.48. The stock has a 50-day moving average of $12.33 and a 200-day moving average of $15.82. Tekmira Pharmaceuticals also saw unusually large options trading on Monday. Traders acquired 10,335 put options on the stock. This represents an increase of approximately 999% compared to the average volume of 940 put options.

A number of analysts have recently weighed in on TKMR shares. Analysts at Maxim Group reiterated a “hold” rating on shares of Tekmira Pharmaceuticals in a research note on Friday. They now have a $23.00 price target on the stock. On a related note, analysts at Clarus initiated coverage on shares of Tekmira Pharmaceuticals in a research note on Thursday, July 31st. They set a “buy” rating and a $22.50 price target on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $26.63.

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (NASDAQ:TKMR) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical partners.

Receive News & Ratings for Tekmira Pharmaceuticals Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tekmira Pharmaceuticals Co and related companies with Analyst Ratings Network's FREE daily email newsletter.